Prognostic role of integrin β1, E-cadherin, and rac1 expression in small cell lung cancer

被引:18
|
作者
Chang, Myung Hee [1 ,5 ]
Lee, Kyungji [2 ]
Lee, Kyo-Young [2 ]
Kim, Yeon Sil [3 ]
Kim, Young Kyoon [4 ]
Kang, Jin-Hyoung [1 ]
机构
[1] Catholic Univ, Div Oncol, Dept Med, Seoul St Marys Hosp,Sch Med, Seoul 137701, South Korea
[2] Catholic Univ, Dept Hosp Pathol, Sch Med, Seoul St Marys Hosp, Seoul 137701, South Korea
[3] Catholic Univ, Dept Radiat Oncol, Sch Med, Seoul St Marys Hosp, Seoul 137701, South Korea
[4] Catholic Univ, Div Pulmonol, Sch Med, Seoul St Marys Hosp,Dept Med, Seoul 137701, South Korea
[5] Ilsan Hosp, Div Hematooncol, Dept Med, Natl Hlth Insurance Corp, Koyang, South Korea
关键词
Small cell lung cancer; integrin ss 1; E-cadherin; rac1; RHO-GTPASES; PANCREATIC-CARCINOMA; CATENIN EXPRESSION; MEDIATED ADHESION; SURVIVAL; HYPERMETHYLATION; ACTIVATION; RECEPTORS; BINDING; IQGAP1;
D O I
10.1111/j.1600-0463.2011.02788.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Integrin beta(1) mediates cellular adhesion to the extracellular matrix (ECM) and is correlated with highly invasive and metastatic behavior in small cell lung cancer (SCLC). E-cadherin (ECAD) is a calcium-dependent cell-cell adhesion receptor that restricts invasion of cells and reduces metastasis. Rac1 is involved in the regulation of the actin cytoskeleton, adhesion, migration, invasion, and tumor metastasis. The aim of this study was to examine integrin beta(1), ECAD and rac1 expression in SCLC and to analyze the prognostic value of these markers in patients with SCLC. We analyzed integrin beta(1), ECAD, and rac1 expression in 112 SCLC tissues by immunohistochemical staining. Correlative analyses between integrin beta(1), ECAD, and rac1 expression and cliniopathological factors were performed. A total of 65 patients had extensive disease (ED) (58%), and 47 had limited disease (LD) (42%). The median follow-up duration was 61 months (range: 14-117 months), and the median progression free survival (PFS) and overall survival (OS) were 6.1 months (range: 4.8-7.4 months) and 9.7 months (range: 8.1-11.3 months), respectively. The expression of integrin beta(1), ECAD, and rac1 protein was observed in 64, 73, and 99 of SCLC tissues, respectively. The correlative analyses between integrin beta(1), ECAD, or rac1 expression and various clinical parameters did not show any statistical significance. However, the ECAD expression was associated with OS in the entire cohort. In contrast, the expression of integrin beta(1) and rac1 was not associated with PFS or OS. In a subgroup analysis, patients with less than two metastasis had significantly longer OS (p = 0.047) if their tumors expressed integrin beta(1) compared to those without integrin beta(1) expression. In addition, OS was longer for patients with ECAD positive tumors compared to those whose tumors did not express ECAD in males (p = 0.032) and patients who never smoked (p < 0.001). Multivariate analysis showed that LD (p = 0.004), overall response rate (p = 0.003), and expression of ECAD (p = 0.015) were the independent good prognostic factors for OS. LD (p = 0.024), overall response rate (p < 0.001), and less than two metastasis (p = 0.003) were prognostic factors for longer PFS. These results suggest that ECAD expression may be useful as a prognostic indicator in patients with SCLC.
引用
收藏
页码:28 / 38
页数:11
相关论文
共 50 条
  • [1] Combined analysis of Rac1, IQGAP1, Tiam1 and E-cadherin expression in gastric cancer
    Walch, Axel
    Seidl, Stefan
    Hermannstaedter, Christine
    Rauser, Sandra
    Deplazes, Joelle
    Langer, Rupert
    von Weyhern, Claus Hann
    Sarbia, Mario
    Busch, Raymonde
    Feith, Marcus
    Gillen, Sonja
    Hoefler, Heinz
    Luber, Birgit
    MODERN PATHOLOGY, 2008, 21 (05) : 544 - 552
  • [2] Lateral Mobility of E-Cadherin Enhances Rac1 Response in Epithelial Cells
    Tsai, J.
    Kam, L. C.
    CELLULAR AND MOLECULAR BIOENGINEERING, 2010, 3 (01) : 84 - 90
  • [3] Prognostic significance of immunohistochemical Rac1 expression in survival in early operable non-small cell lung cancer
    Yuan, Kai
    Qian, Cheng
    Zheng, Ruheng
    MEDICAL SCIENCE MONITOR, 2009, 15 (11): : BR313 - BR319
  • [4] Expression of E-cadherin and β1-integrin mRNA in endometrial cancer
    Wojcik-Krowiranda, Katarzyna
    Forma, Ewa
    Zaczek, Agnieszka
    Brys, Magdalena
    Anna, Magdalena Krzeslak
    Bienkiewicz, Andrzej
    GINEKOLOGIA POLSKA, 2013, 84 (11) : 910 - 914
  • [5] Prognostic Significance of Wnt1, Wnt2, E-Cadherin, and β-catenin Expression in Operable Non-small Cell Lung Cancer
    Wrona, Anna
    Sejda, Aleksandra
    Dziadziuszko, Rafal
    Jassem, Jacek
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2021, 69 (11) : 711 - 722
  • [6] Prognostic Value of E-Cadherin Expression in Non-small Cell Lung Cancer Treated With Gefitinib
    Kook, Eun Hee
    Kim, Yeo Myeong
    Kim, Hyeon Tae
    Koh, Jae Soo
    Choi, Yun Jung
    Rho, Jin Kyung
    Kim, Hye-Ryoun
    Kim, Cheol Hyeon
    Lee, Jae Cheol
    ONCOLOGY RESEARCH, 2010, 18 (09) : 445 - 451
  • [7] Lateral Mobility of E-Cadherin Enhances Rac1 Response in Epithelial Cells
    J. Tsai
    L. C. Kam
    Cellular and Molecular Bioengineering, 2010, 3 : 84 - 90
  • [8] Co-localization of Rac1 and E-cadherin in human epidermal keratinocytes
    Akhtar, N
    Hudson, KR
    Hotchin, NA
    CELL ADHESION AND COMMUNICATION, 2000, 7 (06) : 465 - +
  • [9] Defected expression of E-cadherin in non-small cell lung cancer
    Fei, QY
    Zhang, HT
    Chen, XF
    Wang, JC
    Zhang, RM
    Xu, WQ
    Zhang, Z
    Zou, W
    Zhang, KY
    Qi, QY
    Wang, MH
    Tao, SH
    Luo, ZW
    LUNG CANCER, 2002, 37 (02) : 147 - 152
  • [10] Immunohistochemical analysis of the expression of E-cadherin and ZEB1 in non-small cell lung cancer
    Matsubara, Daisuke
    Kishaba, Yuka
    Yoshimoto, Taichiro
    Sakuma, Yuji
    Sakatani, Takashi
    Tamura, Tomoko
    Endo, Shunsuke
    Sugiyama, Yukihiko
    Murakami, Yoshinori
    Niki, Toshiro
    PATHOLOGY INTERNATIONAL, 2014, 64 (11) : 560 - 568